Waiting For Congress: Reforming, Paying For FDA OTC Monograph Program
This article was originally published in The Pink Sheet
Executive Summary
FDA officials emphasize that without legislation from Congress, the OTC monograph program is not changing, and without a user fee program, the agency couldn’t implement changes.
You may also be interested in...
FDARA Takes Effect With Under-The-Radar Presidential Signature
Key FDA legislation moves to implementation phase with presidential signature but little fanfare.
OTC Monograph User Fees Still On The Table, But Not In Legislation
FDA’s Aug. 23 webinar will update industry stakeholders on progress to modernize its OTC monograph program, but without user fee legislation, new performance goals will not take effect; stakeholders hold out hope a standalone OTC user fee bill could still progress in Congress.
OTC Monograph User Fee Goals Document Beats Authorization To Finish Line
While still awaiting the addition of OTC user fees to pending user fee authorization, and congressional approval of the overall package, FDA has developed guidelines closely tracking Sens. Isakson and Casey's OTC proposal. FDA plans a webinar to update industry on how OTC user fees would work.